In the 1st U19, we established panels of high specificity and high affinity monoclonal antibodies against the following human DC receptors: LOX-1, BDCA-2, DC-SIGN/L, Dectin-1, CD1d, DC-ASGPR, Langerin, CLEC-6, MARCO, CD40 and DCIR. These human DC receptor reagents uncovered fundamental new biology and were used for development of prototype vaccines that target antigens directly to DCs. Based on extensive efficacy data in vitro, as well as preliminary studies in two in vivo models, the Humouse and Rhesus macaque, we hypothesize that the most potent antigen-targeting vaccines will deliver multiple antigens, engage two receptors simultaneously, and will be directly linked to adjuvants. We envision three areas for improvement that are the basis of Aims 1-3.
In Aim 1, we will construct polyvalent vaccines composed of influenza viral hemagglutinin (HA), nucleoprotein (NP), and matrix protein2 (M2). Triple vaccines will induce broad repertoires of both cellular and humoral immune responses.
In Aim 2, we will generate vaccines that target two DC receptors to enhance the immunogenicity of vaccines.
In Aim 3, adjuvant-linked DC-targeting vaccines will be produced. The vaccines generated herein will undergo analysis of DC binding, activation, and internalization through Aim 4, and then undergo further studies within Projects 1-4. Projects 1 and 2 serve, through in vitro analysis, to discover the most potent candidate vaccines - particularly those that will evoke mucosal immunity. The selected vaccines will be tested thoroughly in vivo via Projects 3 and 4.

Public Health Relevance

Vaccine platforms generated and validated in this study will be tested in Project 1-4. Technology obtained in this study will be applied for the generation of vaccines tested in Phase I clinical trials in the near future.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-KS-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor Research Institute
United States
Zip Code
Schmitt, Nathalie; Liu, Yang; Bentebibel, Salah-Eddine et al. (2016) Molecular Mechanisms Regulating T Helper 1 versus T Follicular Helper Cell Differentiation in Humans. Cell Rep 16:1082-95
Salabert, Nina; Todorova, Biliana; Martinon, Frédéric et al. (2016) Intradermal injection of an anti-Langerin-HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo. Eur J Immunol 46:689-700
Kovats, S; Turner, S; Simmons, A et al. (2016) West Nile virus-infected human dendritic cells fail to fully activate invariant natural killer T cells. Clin Exp Immunol 186:214-226
Blohmke, Christoph J; Darton, Thomas C; Jones, Claire et al. (2016) Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid fever. J Exp Med 213:1061-77
Yin, Wenjie; Gorvel, Laurent; Zurawski, Sandra et al. (2016) Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells. EBioMedicine 5:46-58
Ueno, Hideki; Banchereau, Jacques; Vinuesa, Carola G (2015) Pathophysiology of T follicular helper cells in humans and mice. Nat Immunol 16:142-52
Schmitt, Nathalie; Ueno, Hideki (2015) Regulation of human helper T cell subset differentiation by cytokines. Curr Opin Immunol 34:130-6
Joo, HyeMee; Upchurch, Katherine; Zhang, Wei et al. (2015) Opposing Roles of Dectin-1 Expressed on Human Plasmacytoid Dendritic Cells and Myeloid Dendritic Cells in Th2 Polarization. J Immunol 195:1723-31
Akinbobuyi, Babatope; Byrd, Matthew R; Chang, Charles A et al. (2015) Facile syntheses of functionalized toll-like receptor 7 agonists. Tetrahedron Lett 56:458-460
Trobaugh, Derek; Green, Sharone (2015) Of Mice and Men: Protective and Pathogenic Immune Responses to West Nile virus Infection. Curr Trop Med Rep 2:41-48

Showing the most recent 10 out of 120 publications